Physician profile
Eric J Lee
NPI 1801208707
$1,683.45
in general payments reported to CMS, 2019-2025
22 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $76.99 · 2021: $45.92 · 2022: $146 · 2023: $396 · 2024: $600 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $275.64 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $252.60 | 2023-2025 | Orgovyx |
| Stryker Corporation | $244.42 | 2024-2025 | Variax, Mako |
| Glaxosmithkline, LLC. | $181.19 | 2022-2024 | Arexvy, Bexsero, Shingrix |
| Pfizer INC. | $123.42 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $99.20 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $79.61 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $53.89 | 2025 | |
| Merck Sharp & Dohme LLC | $47.93 | 2019-2020 | |
| Amgen INC. | $40.57 | 2019-2023 | Evenity, Prolia |
| Dynavax Technologies Corporation | $39.07 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.37 | 2022 | |
| Novo Nordisk INC | $33.09 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $31.86 | 2022-2023 | |
| Incyte Corporation | $25.20 | 2024 | Jakafi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $21.82 | 2024 | Licart, Tirosint |
| Stemline Therapeutics INC. | $21.47 | 2025 | Elzonris |
| Allergan, INC. | $20.75 | 2020 | |
| Sanofi Pasteur INC. | $14.69 | 2019 | |
| Esperion Therapeutics, INC. | $14.63 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $13.53 | 2024 | Voquezna |
| Linus Health, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.